BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beales ILP. Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab. Dig Dis Sci 2019;64:2688-9. [PMID: 31190203 DOI: 10.1007/s10620-019-05704-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Nhu QM, Aceves SS. Current state of biologics in treating eosinophilic esophagitis. Ann Allergy Asthma Immunol 2023;130:15-20. [PMID: 36243282 DOI: 10.1016/j.anai.2022.10.004] [Reference Citation Analysis]
2 Racca F, Pellegatta G, Cataldo G, Vespa E, Carlani E, Pelaia C, Paoletti G, Messina MR, Nappi E, Canonica GW, Repici A, Heffler E. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets. Front Physiol 2022;12:815842. [DOI: 10.3389/fphys.2021.815842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Keshvari MK, van Someren F, Sheikh S, Galea I. Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns. J Neuroimmunol 2021;361:577729. [PMID: 34624660 DOI: 10.1016/j.jneuroim.2021.577729] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Diem L, Hoepner R, Bagnoud M, Salmen A, Chan A, Friedli C. Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature. J Neuroimmunol 2021;353:577505. [PMID: 33548621 DOI: 10.1016/j.jneuroim.2021.577505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]